Randomized trial · people

Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes, an oral, once-daily form of amycretin lowered HbA1c more than placebo at all three doses tested, with gut side effects becoming more common at higher doses.

Kind
Randomized trial
Studied in
People
Number studied
186
Published
2026
Journal
Lancet

What they tested

The team tested how different doses of once-daily oral amycretin (zenagamtide), a single molecule that acts on GLP-1, amylin and calcitonin receptors, change blood sugar control and safety compared with placebo in type 2 diabetes.

How the study was done

A randomized, double-blind, placebo-controlled, phase 2 dose-finding trial in 186 adults with type 2 diabetes already taking metformin, with or without an SGLT2 inhibitor, at 83 sites in 11 countries. Participants got 6, 25 or 50 mg of oral amycretin or a matching placebo (a dummy treatment) for 36 weeks, with doses stepped up from 1.5 mg every 4 weeks until each arm's target dose was reached.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c (a 3-month average of blood sugar) started at a mean of about 7.9% to 8.1%. By week 36 it fell by 0.9% in the 6 mg arm, 1.3% in the 25 mg arm and 1.4% in the 50 mg arm; compared with placebo, the differences were -0.5%, -0.99% and -1.09%, all statistically significant. Stomach and gut side effects were the most common, seen in 26% of the 6 mg arm, 41% of the 25 mg arm, 47% of the 50 mg arm and 23% of the placebo arm. Serious adverse events occurred in 7 participants, all taking amycretin (2, 2 and 3 across the dose arms), none on placebo, and nobody died.

What it doesn’t show

This was a mid-stage trial lasting 36 weeks with only 30 people on placebo, so it can't show longer-term effects or rarer side effects. It only included people with type 2 diabetes on metformin, and it was funded by Novo Nordisk.

The paper

Mora et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026.

The compound

More studies on Amycretin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo